GB0602855A
GB0602855D0
(en)
|
2006-02-13 |
2006-02-13 |
The Treatment Of Sialorrhoea
|
NZ570492A
NZ570492A
(en)
|
2006-02-13 |
2007-02-12 |
Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of excess salivation or drooling
|
MYPI20083081A
MY145817A
(en)
|
2006-02-13 |
2007-02-12 |
Combination of alpha-2 receptor agonist (clonidine) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
|
JP2008554857A
JP5296557B2
(en)
|
2006-02-13 |
2007-02-12 |
Combination of alpha-2 receptor agonist (clonidine) and antimuscarinic agent (oxybutynin) for the treatment of fluency
|
ES07705370.0T
ES2442694T3
(en)
|
2006-02-13 |
2007-02-12 |
Combination of an alpha 2 receptor agonist (clonidine) and an antimuscarinic agent (oxybutynin) for the treatment of sialorrhea
|
EP12181773.8A
EP2526943B1
(en)
|
2006-02-13 |
2007-02-12 |
Liquid formulation comprising an alpha-2 receptor agonist (e.g. clonidin) and oxybutynin (anti-muscarinic agent) for the treatment of sialorrhoea
|
DK12181773.8T
DK2526943T3
(en)
|
2006-02-13 |
2007-02-12 |
LIQUID FORMULATING INCLUDING AN ALPHA-2 RECEPTOR AGONIST (E.g. CLONIDIN) AND OXYBUTYNIN (ANTIMUS CARININE) FOR THE TREATMENT OF SPIT
|
KR1020087022049A
KR101370096B1
(en)
|
2006-02-13 |
2007-02-12 |
Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
|
CA2642850A
CA2642850C
(en)
|
2006-02-13 |
2007-02-12 |
Combination of alpha-2 receptor agonist (clonidine) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
|
PT77053700T
PT1986642E
(en)
|
2006-02-13 |
2007-02-12 |
Combination of alpha-2 receptor agonist (clonidine) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
|
DK07705370.0T
DK1986642T3
(en)
|
2006-02-13 |
2007-02-12 |
Combination of alpha-2 receptor agonist (clonidine) and an antimuscarinic agent (oxybutynin) for the treatment of sialorrhoea
|
ES12181773.8T
ES2624577T3
(en)
|
2006-02-13 |
2007-02-12 |
Liquid formulation comprising an agonist of the alpha-2 receptors (eg, clonidine) and oxybutynin (antimuscarinic agent) for the treatment of sialorrhea
|
EP07705370.0A
EP1986642B1
(en)
|
2006-02-13 |
2007-02-12 |
Combination of alpha-2 receptor agonist (clonidine) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
|
PT121817738T
PT2526943T
(en)
|
2006-02-13 |
2007-02-12 |
Liquid formulation comprising an alpha-2 receptor agonist (e.g. clonidin) and oxybutynin (anti-muscarinic agent) for the treatment of sialorrhoea
|
CN200780009158.3A
CN101400347B
(en)
|
2006-02-13 |
2007-02-12 |
Alpha-2 receptor agonist (clonidine) is combined with antimuscarinic drug (oxibutynin) and is used for the treatment of sialorrhea
|
US12/279,217
US8481583B2
(en)
|
2006-02-13 |
2007-02-12 |
Combination of alpha-2 receptor agonist (clonidin) and anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
|
AU2007216320A
AU2007216320B2
(en)
|
2006-02-13 |
2007-02-12 |
Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
|
PCT/GB2007/050057
WO2007093824A1
(en)
|
2006-02-13 |
2007-02-12 |
Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
|
HK09108445.5A
HK1129595A1
(en)
|
2006-02-13 |
2009-09-15 |
Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea 2 ()()
|
US13/593,173
US8658683B2
(en)
|
2006-02-13 |
2012-08-23 |
Combination of alpha-2 receptor agonist (clonidin) and anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
|
JP2013064062A
JP5744947B2
(en)
|
2006-02-13 |
2013-03-26 |
Combination of alpha-2 receptor agonist (clonidine) and antimuscarinic agent (oxybutynin) for the treatment of fluency
|